Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.
CMS Officials Pressed on Catheter Fraud Issue at Accountable Care Meeting
The Centers for Medicare & Medicaid Services (CMS) officials speaking on a panel at an annual gathering of accountable care organizations (ACOs) in Baltimore were